Propanamine derivatives for treating pain and pain related conditions

A compound of general formula (I):

• wherein:
• R1 and R′1 are independently selected from a hydrogen atom and a branched or unbranched C1-6 alkyl radical;
• R2 is 6-membered aryl optionally substituted by a halogen atom, a branched or unbranched C1-6-alkyl radical, a branched or unbranched C1-6-alkoxy radical, a C1-6-haloalcoxy radical, a C1-6-haloalkyl radical or a hydroxyl radical;
• or a substituted or unsubstituted 5 or 6-membered heteroaryl having at least one heteroatom selected from N, O and S;
• n is 1;
• m is 0 or 1;
• W is —(CH2)p—;
• —C(O)—;
• or a bond;
• p is 1 or 2;
• Z is NR3R4;
• R3 is a hydrogen atom;
• a branched or unbranched C1-6 alkyl radical;
• a benzyl radical;
• or a phenyl radical;
• R4 is a branched or unbranched C1-6 alkyl radical optionally substituted by a halogen atom, a hydroxyl radical, a branched or unbranched C1-6 alkoxy radical or a —NR4aR4b radical;
• a —(CH2)s-heteroaryl radical, wherein the heteroaryl group is a 5 or 6-membered ring having at least one nitrogen atom as heteroatom, optionally substituted by a —NR4cR4d radical, and s is 0, 1 or 2;
• a heterocycloalkyl radical optionally substituted by R4e;
• a —(CH2)r-aryl radical wherein the aryl group is 6-membered ring optionally substituted by at least one R5 radical, and r is 0, 1 or 2;
• or a —C(O)R5 radical;
• R4a, R4b, R4c, R4d and R4e are independently selected from the group consisting of a hydrogen atom and a branched or unbranched C1-6 alkyl radical;
• R5 is a hydrogen atom;
• a hydroxyl radical;
• a branched or unbranched C1-6-alkoxy radical;
• a —(CH2)j—NR5aR5b radical;
• a —NR5cR5d radical;
• or a 5-membered heteroaromatic ring having one or more N and/or O as heteroatoms, optionally substituted by R5e;
• R5a, R5b, R5c, R5d and R5e are independently a hydrogen atom or a branched or unbranched C1-6 alkyl radical;
• j is 0 or 1;
• R6 is a branched or unbranched C1-6 alkyl radical;
• a —(CH2)q—NR6aR6b radical;
• a 5 or 6-membered nitrogen containing heteroaryl ring optionally having at least one additional heteroatom selected from O and N and optionally substituted by at least one R7;
• or a 6-membered aryl optionally substituted by at least one R8;
• R6a and R6b are independently selected from the group consisting of a hydrogen atom and C1-6 alkyl;
• q is 0, 1, 2, 3 or 4;
• R7 is selected from the group consisting of a hydrogen atom, a branched or unbranched C1-6-alkoxy radical, a branched or unbranched C1-6-alkylthio radical;
• a —NR7aR7b radical;
• and a 5-membered heterocycloalkyl ring having at least one heteroatom selected from O, N and S;
• R7a and R7b are independently selected from the group consisting of H and C1-6 alkyl;
• R8 is a hydrogen atom, a halogen atom, a branched or unbranched C1-6-alkyl radical or a —(CH2)t—NR8aR8b radical;
• t is 0 or 1;
• R8a and R8b are independently selected from the group consisting of a hydrogen atom and a branched or unbranched C1-6 alkyl radical;
• or a pharmaceutically acceptable salt, isomer, or solvate thereof.